SCHEMBL16740249

SCHEMBL16740249

Cc1nc2ncc(Cl)cc2n1-c1cncc(Nc2ccc(OC(F)(F)F)cc2)n1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 5/20 0.47
SCN5A Q14524 4/20 0.47
SCN9A Q15858 4/20 0.47
BRAF P15056 2/20 0.41
ABL1 P00519 9/20 0.40
BCR P11274 9/20 0.40
GALR2 O43603 1/20 0.37
CTSC P53634 1/20 0.37
ADRB3 P13945 1/20 0.36
TSPO P30536 1/20 0.36
GRM5 P41594 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
GPR35 Q9HC97 1/20 0.36
KDR P35968 1/20 0.36
DHFR P00374 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16740060 0.90 KCNH2 (0.45) KCNH2SCN5ASCN9ABRAFABL1
SCHEMBL16740021 0.87 BMI1 (0.43) KCNH2SCN5ASCN9ABRAFABL1
SCHEMBL16740374 0.87 BMI1 (0.46) KCNH2SCN5ASCN9AGALR2DHFR
SCHEMBL16747970 0.86 KCNH2 (0.48) KCNH2SCN5ASCN9ABRAFABL1
SCHEMBL16740073 0.86 KCNH2 (0.48) KCNH2SCN5ASCN9ABRAFABL1
SCHEMBL16740316 0.85 KCNH2 (0.49) KCNH2SCN5ASCN9ABRAFABL1
SCHEMBL16739903 0.84 CDK2 (0.45) KCNH2SCN5ASCN9ABRAFKDR
SCHEMBL16740231 0.83 KCNH2 (0.49) KCNH2SCN5ASCN9ABRAFABL1
SCHEMBL16740257 0.82 KCNH2 (0.50) KCNH2SCN5ASCN9ABRAFABL1
SCHEMBL16739937 0.81 KCNH2 (0.49) KCNH2SCN5ASCN9ABRAFABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 US claimed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US claimed
EP-3071553-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC Therapeutics, Inc. (US) 2016-09-28 EP claimed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO claimed
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors PTC THERAPEUTICS, INC. (US) 2020-03-10 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. 2016-09-29 US disclosed
WO-2015076800-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS PTC THERAPEUTICS, INC. (US) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160280685-A1 SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS BMI1, BAZ2A, BAZ2B KCNH2 3952/4885SCN5A 3115/4885SCN9A 4295/4885
US-10584115-B2 Substituted pyridine and pyrazine BMI-1 inhibitors BMI1, BAZ2A, BAZ2B KCNH2 3952/4885SCN5A 3115/4885SCN9A 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.